INTEGRATED CORE STRATEGIES (US) LLC → Quince Therapeutics, Inc. QNCX

Stake: — Shares: — Class: Common Stock, par value $0.001 per share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

6 filings by this filer

5 other filings in the data moat

Short Interest · settle 2026-07-15

DTC 1.18

50,574 shares short · -55.2% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $281K

Point72 Asset Mgmt

Other Filings by INTEGRATED CORE STRATEGIES (US) LLC

Filed	Form	Issuer	Stake	Shares
2026-06-18	SCHEDULE 13G	Edesa Biotech, Inc. EDSA	—	—	view →
2026-06-17	SCHEDULE 13G	TPG Inc. TPGXL	—	—	view →
2026-06-11	SCHEDULE 13G	Once Upon a Farm, PBC OFRM	—	—	view →
2026-05-26	SCHEDULE 13G	Amanat Acquisition Corp AMAN	—	—	view →
2018-01-08	SC	TETRAPHASE PHARMACEUTICALS INC	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →